glp-1 produced by and the kidney: from physiology to pharmacology and outcomes in diabetes Glucagon-like peptide-1 - Wikipedia

Kosowska, A

This study is the first to examine the potential cardiovascular benefits of these drugs in a high-risk population of patients with both obesity and an autoimmune diseaseboth of which are associated with a higher risk of cardiovascular and blood clot events

This suggests that the antiatherosclerotic effects of short-term GLP-1 may not play a central role in atherosclerosis

2023, Harvard Health Publishing

"Without addressing the underlying causes [of obesity ] whether through lifestyle changes, behavioral interventions, or personalized treatment weight loss may not be sustainable, explains Andres Acosta, MD, PhD , associate professor of medicine at Mayo Clinic